InsiderTrades

Form 4 for PTGX Protagonist Therapeutics, Inc

Accepted 2024-03-01 00:00:00 ET · period of report 2024-02-29 · accession 0001104659-24-030156 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2024-03-01 2024-02-29+ PTGX Ali Asif CFO S - Sale+OE $31.60 -24.2K 42.7K -36% -$764.4K
D 2024-03-01 2024-03-01 PTGX Ali Asif CFO M - OptEx $12.17 +12.0K 52.6K +30% +$146.0K
D 2024-03-01 2024-03-01 PTGX Ali Asif CFO M - OptEx $0.00 -12.0K 51.8K -19% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-03-01 S D 2,248 $32.33 38,397 D — — (F3) The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $32.28 to $32.39. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
2 Common Common Stock 2024-02-29 S D 2,089 $31.00 40,645 D — —
3 Common Common Stock 2024-03-01 S D 12,000 $32.22 40,645 D — — (F2) The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $32.17 to $32.31. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
4 Common Common Stock 2024-03-01 M A 12,000 $12.17 52,645 D — —
5 Common Common Stock 2024-02-29 S D 7,850 $30.61 42,734 D — — (F1) The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $30.57 to $30.76. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
6 Derivative Stock Option (right to buy) 2024-03-01 M D 12,000 $0.00 51,750 D $12.17 · — to 2033-01-15 12,000 Common Stock (F4) The stock option was granted to the Reporting Person on January 16, 2023 and vests in 48 equal monthly installments following the date of grant.